Consider writing about:
The Chapter 11 filing by biotech company Sangamo Therapeutics; issues leading up to the gene-editing company’s bankruptcy; what to know about an agreement by Eli Lilly and Japanese drugmaker Astellas to act as “stalking horse” bidders; how the “stalking horse” process works in a bankruptcy, and what parties on each side of the agreement should know before agreeing to participate in such an endeavor; and perhaps a wider-angle look at the biotech industry, its overall financial health, competition trends, and challenges facing either the industry as a whole or other specific biotech companies right now.